T 0317/95 (Gastrointestinal compositions/PROCTER & GAMBLE) 26-02-1999

Reasons for the Decision

1. The appeal is admissible.

2. Amendments (Articles 84, 123(2) and (3) EPC)

The claims as amended by the appellants during the opposition or opposition appeal proceedings comply with the provisions of Articles 84 and 123(2) and (3) EPC. Since the admissibility of the requests on file in these formal respects was not disputed by the respondents, there is no need for further detailed substantiation of this matter.

3. Publication date of citations (1), (6), (1/6); state of the art (Article 54(2) EPC)

It is undisputed that the patent in suit enjoys the priority of an earlier application in USA on 9 March 1987. Citation (1) is entitled "De-NolR: Mucosal Protection and Peptic Ulcer Disease; Proceedings of the De-Nol Symposium, 8 September 1986, The World Congress of Gastroenterology, Sao Paulo"; it bears in the top left-hand corner of the front page the remark "Released June 1987".

It has, however, never been contested by the appellants during the entire proceedings that citation (1) and, accordingly, citations (6) and (1/6) represent a true and authentic account of the earlier oral disclosure during the symposium mentioned above. The content of the above mentioned citations is therefore considered as comprised in the state of the art within the meaning of Article 54(2) EPC.

4. Novelty (Article 54(1) EPC); patentability under the terms of Article 52(4) EPC

4.1. Lack of novelty of claim 10 of the main request over the disclosure of citation (1/6) is one of the grounds on which the oppositions are based and which was brought up by respondents 02 during oral proceedings before the board. The opposition division explicitly acknowledged the novelty of claim 10 in point 2 of the reasons for the decision (see paragraph IV above).

The respondents' objection to the lack of novelty of claim 10 is based, inter alia, on the argument that the limitation introduced in said claim during opposition proceedings to concurrent administration of both the bismuth-containing agent and the H2-receptor blocking agent related to a method of treatment of the human or animal body by therapy and that, according to the established case law of the boards of appeal, subject-matter excluded from patentability under Article 52 EPC could not be relied upon to distinguish the alleged invention over the cited prior art according to (1/6).

4.2. Indeed, citation (1/6) already describes the possible benefit of the combined therapy of a bismuth-containing agent, more specifically CBS, and an H2-receptor blocking anti-secretory agent, more specifically cimetidine, in the treatment of gastrointestinal disorders. According to the drug regimen prescribed for the treatment disclosed in citation (1/6), CBS tablets were given as 2 tablets twice a day, the first half an hour to 1 hour before breakfast, and the second half an hour before the last meal of the day; cimetidine was given as 2 tablets at bedtime (see page 44, right hand column, first full paragraph).

If this disclosure of the state of the art is compared with the claimed subject-matter in the contested patent, it is found that the combined use of the two active agents, ie CBS and cimetidine, disclosed in citation (1/6) does not differ from the use claimed in claim 10 of the main request (see paragraph II above) with regard to the combination of the two single active agents used and the therapeutic application of the medicament for the treatment or prevention of gastrointestinal disorders in humans or animals. Claim 10 is in no way restricted to the medicament being manufactured in any particular concentration, dosage or formulation either.

Hence, the sole difference between the prior art of (1/6) and the subject-matter of claim 10 resides in the prescribed treatment regimen used for administering the bismuth-containing agent on the one hand, and the H2 -receptor blocking anti-secretory agent, on the other, to an individual patient in need of them. The regimen in (1/6) comprises administering said bismuth-containing agent half an hour before the last meal of the day and said H2-receptor blocking anti-secretory agent at bedtime, whereas according to present claim 10 these two active agents are administered within 5 minutes of each other, e.g. concurrently.

4.3. Therefore, the issue of novelty raised by the respondents essentially concerns the question of whether the mere difference in the course of the administration of the two drugs or, expressed differently, the difference in the prescribed regimen, could indeed confer novelty on claim 10. Moreover, the respondents' objections to claim 10 appear to imply the issue of the patentability of the subject-matter of claim 10 under the terms of Article 52(4) EPC.

In the parallel decisions G 1/83, G 5/83 and G 6/83 (OJ ECO 1985, 60, 64, 67, cited in the following as G 5/83), relied on for the assessment of novelty of claim 10 by the appellants in their submissions and the opposition division in its decision, the Enlarged Board of Appeal allowed claims in a specific format for a further medical indication. According to Order no. 2 of the above decisions, an European patent may be granted with claims directed to the use of a substance or composition for the manufacture of a medicament for a specified new and inventive therapeutic application.

In the context of the question of law referred to the Enlarged Board for appeal in the above decisions ("Can a patent directed to the use be granted for the use of a substance or composition for the treatment of the human or animal body by therapy ?"; see summary, paragraph I) the Enlarged Board of Appeal considered as a further medical indication the use of a substance, already known as a medicament, to treat an illness or disease not previously treated by means of that substance (see G 5/83, especially reasons, point 17, 2nd paragraph). While the treatment of a different illness or disease, was specifically recognised in decision G 5/83 to represent a new therapeutic application (further medical indication) of a medicament known per se, this does not yet exclude the possibility of deriving a second or further medical indication (a new therapeutic application) of a substance or composition, already known as a medicament, likewise from some other, previously unknown feature or embodiment (than treatment of a different illness or disease) associated with the use of that substance or composition in a method for the medical treatment of the human or animal body. In this respect reference is made to the boards of appeal case law, for example, as summarized in "Case Law of the Boards of Appeal of the European Patent Office", 3rd edition, 1998, section I.C. 6.2.2; "Novelty of the new therapeutical application."

4.4. When applying the criteria set forth above to the present case it is found that both the cytoprotective agent BNS, on the one hand, and the acid-suppressing agent cimetidine, on the other, were at the priority date well-known and widely used commercially available drugs which had already been administered for years by doctors to patients for the treatment of duodenal ulcer and other gastrointestinal disorders [cimetidine, for example, had been introduced in 1976, see (3), top of page 221] and the activities, effects and possible side-effects of which had already been exhaustively documented [see, as examples only, citations (1), (3) and (16)].

In the context of the present case it appears particularly important to note that the combined or simultaneous therapy of both CBS and cimetidine in the treatment of patients suffering from duodenal ulcer had also already been initiated before the priority date by a hospital doctor specialised in gastroenterology, namely Dr P. R. Salmon (see 1/6), as a pure therapeutic method with the aim to provide an improved treatment of gastrointestinal disorders. This combined therapy involves separately administering both the commercially available drugs BNS and cimetidine to patients in need of them, using a certain prescribed regimen referred to by Dr Salmon in citation (1/6) and mentioned in point 4.2 (above).

The invention as such which forms the subject-matter of claim 10 in fact involves the treatment of exactly the same category of patients by separately administering to them exactly the same two commercial drugs in the same concentration, dosage and formulation (see page 3, line 56 to page 5, line 25 of the contested patent) for the treatment of entirely the same illness or disease, with the sole exception that the prescribed regimen for this treatment is slightly modified (BNS and cimetidine are administered to the patient within five minutes of each other). It appears therefore difficult to recognise in the present invention a new field of therapeutic application or any further medical indication in general associated with the claimed combined use of the bismuth-containing agent and an H2-receptor blocking anti-secretory agent.

4.5. In considering of whether the instruction in claim 10 concerning the particular course of the administration of the two known drugs (ie the prescribed regimen) for the treatment of gastrointestinal disorders may be regarded as relating to a further medical indication, sight should not be lost of the reasons for which the Enlarged Board of Appeal allowed claims for a second or further medical indication in analogy to the fiction of novelty for first medical indications laid down in Article 54(5) EPC. The Enlarged Board stated that it is the purpose of the exclusion of medical treatments from patentability according to Article 52(4) EPC to free from restraint non-commercial and non-industrial medical and veterinary activities. To prevent the exclusion in Article 52(4) EPC from going beyond its proper limits it seemed appropriate to take a special view of the concept of the state of the art for second and further medical indications. It was apparently the intention of the Enlarged Board of Appeal to allow claims directed to a further medical indication, in order to provide a certain compensation for the restriction on patent rights in the industrial and commercial field resulting from Article 52(4) EPC, first sentence (see G 5/83, especially reasons, point 22).

This suggests that, when it comes to the assessment of the possible limits of what could indeed be recognised to be a further medical indication (new therapeutic application) within the meaning of decision G 5/83, it appears appropriate to consider the question of whether the sole distinguishing feature, which was introduced in the claim directed to a further medical use for the purpose of delimiting the claimed subject-matter from the prior art, relates to non-commercial and non-industrial medical activities.

The board has no reason to question the appellants' submission that the pharmaceutical industry, too, is engaged in optimizing the use of drugs and medicaments by investigating the optimum regimen for their administration to achieve the maximum possible therapeutic effect. Notwithstanding this, determination of the best individual treatment schedule, in particular the prescribing and modification of drug regimens used for administering a particular medicament, so as to comply with the specific needs of a patient, appear to be in the first place part of the typical activities and duties of the doctor in attendance in exercising his professional skills of curing, preventing or alleviating the symptoms of suffering and illness. These are, however, typical non-commercial and non-industrial medical activities which Article 52(4) EPC intends to free from restraint.

In any case, before the priority date of the contested patent, the medical practitioner was in the present case aware of the possibility of treating gastrointestinal disorders using the particular combination of drugs defined in claim 10. He was similarly in a position to prescribe an effective regimen for treating each patient according to his individual needs (see citation (1/6), loc. cit.)

In view of the preceding it appears questionable to the board whether the feature in the last half-sentence of claim 10, which in fact relates to the prescribing of a specific drug regimen for a basically known medical treatment, more specifically, to the concurrent administration of both the bismuth-containing agent and the H2-receptor blocking agent for the treatment of gastrointestinal disorders, could indeed be considered to represent a further medical indication from which novelty could be derived on the basis of the principles set out in decision G 5/83.

It appears questionable, too, whether this feature indeed reflects a medical activity in the industrial and commercial field not excluded from patentability within the terms of Article 52(4) EPC, as maintained by the appellants.

4.6. Since the main request and similarly the auxiliary requests have in any case to be dismissed on the ground to be dealt with in point 5 (below), there is no need to give a decision on the respondents' objections to claim 10 on the ground of lack of novelty and non-patentability under the terms of Article 52(4) EPC.

The novelty of claim 1 of the main request and the second auxiliary request was not contested and can, in the board's judgment, be acknowledged, as can the novelty of the claims of the first and third auxiliary requests, since neither the formulation of a bismuth-containing agent and an H2-receptor blocking agent into a single combined product, nor the administration of ranitidine as the specific H2-receptor blocking agent in combination with a bismuth-containing agent for the treatment of gastrointestinal disorders can be derived from the cited state of the art. The issue in the present case is therefore that of inventive step.

5. Inventive step (Articles 52(1) and 56 EPC)

5.1. With respect to inventive step the opposition division referred in point 3.1 of the reasons for the impugned decision to citation (1/6) and equally to citation (2) as the most relevant state of the art. The Pounder paper (2) likewise discloses the use of cytoprotective bismuth-containing agents and acid-suppressing H2-receptor blocking anti-secretory agents, eg cimetidine and ranitidine, in the treatment and prophylaxis of duodenal ulceration. In the fourth full paragraph on page 699, citation (2) provides the skilled reader with the conclusive teaching that maximal "Band-Aid" activity might occur during simultaneous treatment of ulcer patients with tripotassium dicitrato bismuthate and an H2-antagonist without giving any further details about the conditions or methods used in this simultaneous treatment, for example, as far as the prescribed regimen for the administration of these two active agents is concerned.

The board concurs with the opinion of the opposition division that the expression "simultaneous treatment" used in (2) necessarily includes the option of concurrently or simultaneously administering the said two active agents to an individual patient but does not exclude any other possible treatment regimens for the combined therapy, for example, administration of the two active agents more or less widely spaced apart in time.

Since citation (1/6) does not only disclose the possibility of treating patients suffering from gastrointestinal disorders with a bismuth containing agent and an H2- receptor blocking anti-secretory agent simultaneously, but also furnishes the skilled reader with certain details as to the combination of the specific medicaments administered and, in particular, the regimen used in said treatment (see point 4 above), it is considered to be closer to the subject-matter of the invention than citation (2). Moreover, the results of the combined therapy reported in (1/6) already indicate a significant increase in the short term (4 weeks) healing rate of ulcer patients compared to the treatment with CBS or cimetidine alone (see especially page 45, Table VI; Conclusion).

5.2. In submitting at the appeal stage some comparative tests in the declaration by Dr Carryl, the appellants apparently wanted to take account of the fact that in the present case the state of the art according to citation (1/6) approaches the subject-matter of the patent in suit so closely that it is necessary to submit an indication of inventive step. The comparative tests submitted purport to demonstrate that the problem which had been solved by the claimed invention was the provision of a more effective therapy for gastrointestinal disorders mediated by the microorganism H. pylori (formerly known as Campylobacter pyloridis).

If comparative tests are chosen to demonstrate an inventive step on the basis of an unexpected effect, such tests must meet certain criteria. These include the maximum possible adherence to the instructions, parameters and conditions used in the closest state of the art to make sure that the tests provide a true and reliable account of the results achieved when carrying out the teaching of the state of the art and that the claimed effect has indeed its origin in the distinguishing feature of the invention over what is in fact disclosed in the closest state of the art.

The requirements set forth above are not met in the present case since in the comparative tests submitted the course of administering CBS and cimetidine disclosed in citation (1/6) has not been followed. In spite of the fact that in the context of the present invention the course of administration appears crucial to the definition of the problem to be solved, no reasonable explanation could be provided on the part of the appellants during oral proceedings why in the comparative tests a CBS solution was administered to the test animals 4 hours after the H2- receptor blocker ranitidine was given, whilst in the prior art of (1/6) the active drugs were administered in reverse order, ie CBS was given before the H2-receptor blocker cimetidine was administered.

For other reasons, too, it appears in the board's opinion questionable whether the comparative evidence provided could indeed support the appellants' allegation that the claimed invention would provide a more effective therapy for gastrointestinal disorders mediated by the microorganism H. pylori. This allegation is effectively based on the finding that simultaneous administration resulted in increased levels of bismuth and its longer residence in the stomach of animals and the as yet unproven conclusion that an increased cytoprotective effect of the bismuth agent found in animal experiments would indeed result in a more effective therapy for gastrointestinal disorders.

At the top of the right-hand column on page 61 of (1) it is, however, stated that the cytoprotective effects of CBS seen in animal experiments and the actual ulcer-healing properties of the drug are believed to be unconnected, since cytoprotection constitutes the mechanism by which damage is prevented while healing is the process of repairing damage already done.

Consequently, the alleged but only insufficiently supported advantageous effect cannot be taken into consideration for the determination of the problem underlying the claimed invention and hence also not for the assessment of the inventive step.

5.3. Given (1/6) as representing the closest state of the art the technical problem the invention sets out to solve may therefore be seen as that of simplifying the combined treatment of gastrointestinal disorders with a bismuth-containing agent and an H2- receptor blocking anti-secretory agent to improve compliance without impairing the beneficial therapeutic effect achieved by the combined therapy. Simplification is in any case a reasonable and desirable objective which the skilled person would obviously seek to achieve. In the particular field of therapeutic treatment simplification of the patient's regimen affords, inter alia, the advantage of minimising the permanent risk of deviation from the prescribed drug treatment which may cause total or partial failure of the therapy (see in this respect, as an example only, citation (17), especially page 688: discussion).

The solution to this problem suggested in the contested patent is to combine the bismuth-containing agent and the H2-receptor blocking agent in a single pharmaceutical composition (claim 1 of all requests on file) or to administer these two active agents separately within 5 minutes of each other (claim 10 of the main request, claim 8 of the first auxiliary request). It has not been contested by the respondents and the board has no reasonable doubts that the combined formulation or concurrent administration plausibly solves the technical problem defined above.

5.4. With reference to the observations in the foregoing points and the state of the art according to (1/6) and (2) the board is of the opinion that the skilled person in the present case is a specialist in gastroenterology or a team of specialists of that skill aiming to simplify the known combined therapy and to improve compliance. The appellants' allegation that there was at the priority date a certain concern about possible detrimental interactions between the two particular kinds of drugs used in the present simultaneous treatment requiring the assistance of a clinical pharmacologist does not find any support in the cited state of the art and has likewise not been substantiated in the appellants' submissions.

As is stated at page 43, right-hand column of (1/6), the aims of the combined therapy in (1/6) were to compare the efficacy of CBS alone, or cimetidine alone versus that of the combination of CBS and cimetidine in the treatment of duodenal ulcer, in order to improve the medical treatment of peptic ulceration. Under these circumstances it appears reasonable that Dr. Salmon adhered in his study for the purpose of comparison to the conventional course used for administering the single active agents in order to obtain reliable results on the possible benefit of the combined therapy.

However, the specialist who was interested in taking advantage of the benefits achieved by using the combined therapy disclosed in (1/6) in his daily practice and whose principal aim is treatment would obviously attempt to make his patients' regimen as simple as possible, in order to improve patient compliance. Compliance is known to be a particular problem in out-patient populations where the prescribed drug regimen does not come under the permanent observation of a medical practitioner. It should be noted that non-compliance represents several risks and is a major cause of failure of treatment regimens.

In this context, the skilled person would have felt at the priority date of the contested patent a strong incentive to solve the problem defined above by administering the bismuth-containing agent and the H2-receptor blocking anti-secretory agent concurrently, preferably simultaneously, as for the reasons given above concurrent administration may have certain benefits that even outweigh theoretical disadvantages.

Having learned from (1/6) the advantages of the combined therapy, the skilled formulator in the pharmaceutical industry would obviously have deemed the provision of a single pharmaceutical preparation for co-administration of the two active agents to represent a particularly convenient and attractive pharmaceutical dosage form to facilitate implementation of the combined therapy.

5.5. The appellants' arguments in support of inventive step are essentially based on the allegation that there existed at the priority date a prejudice against simultaneous administration of a bismuth-containing agent and an H2-receptor blocking anti-secretory agent. It is accepted that inventiveness could sometimes be established by demonstrating that a known prejudice, ie a widely held but incorrect opinion of a technical fact, needed to be overcome.

The burden is on the appellants to demonstrate that the alleged prejudice really existed. The existence of a prejudice should normally be demonstrated by reference to handbooks representing the general, commonly accepted specialist knowledge and encyclopaedias published before the priority date. Any prejudice which might have developed after the priority date is of no concern in the judgment of inventive step.

Contrary to the requirements set forth above, there was no evidence provided to adequately support the appellants' contention that in the present case at the priority date of the claimed invention a prejudice existed in the state of the art which would have diverted the skilled person away from simultaneous or common administration of the two active agents. It rather appears that, in the absence of a real prejudice in the sense outlined above, the appellants made in their submissions an ex post facto attempt to create a prejudice, which in fact did not exist, by more or less arbitrarily selecting certain isolated disclosures from the state of the art and purposively combining them with the benefit of hindsight.

In fact, contrary to there being a prejudice against simultaneous administration, the Pounder paper (2) refers in full paragraph 4 on page 699 to possible advantages of simultaneous treatment which clearly includes the obvious option of simultaneously administering both the bismuth-containing agent and the H2-antagonist. The appellants allegation that a prejudice had existed is therefore not readily understood, because both citation (1/6) - see especially top right-hand column on page 43 - and likewise citation (2) - see lines 1 to 3 of paragraph 4 on page 699 - underline the fact that optimal precipitation of bismuth in the stomach occurred when the pH was between 2.5 and 3.5, whilst the median 24-hour intragastric pH was 1.4 in untreated duodenal ulcer cases and that, precisely for this reason, the combined use of a bismuth-containing agent and an H2- receptor blocking anti-secretory agent having the capability of raising the pH to the desired level was recommended as particularly attractive for short term healing.

The appellants provided no evidence in support of their assertion that the effectiveness of the bismuth agent in gastrointestinal therapy was indeed believed to be reduced or to deteriorate by the concurrent administration of an H2-receptor blocking anti-secretory agent or that simultaneous administration was indeed believed to bear any risk due to potential interactions between the two drugs.

The appellants' reference in this respect to Prof. Konturek's advice in citation (1) at page 61 (see especially right-hand column, second paragraph) against the taking of antacids too closely to doses of CBS is similarly not of any help in supporting the existence of a prejudice. It is an undisputed fact that antacids have different effects compared to H2-receptor blocking anti-secretory agents upon administration. While antacids neutralise the pH in the gastrointestinal tract immediately after ingestion as a result of interaction between the antacid and the hydrochloric acid in the stomach, H2-receptor blockers are systemic drugs and do not cause a significant rise in the intragastric pH for a latency period of 30 minutes or more - see citation (3). Hence, in the absence of any evidence to the contrary, the skilled person would not assume that the advice given in (1) applies to the administration of H2-receptor blockers as well.

5.6. It was further asserted on the part of the appellants that, in order to achieve effective bismuth precipitation, it was believed at the priority date to be necessary or at least advantageous to have raised the intragastric pH [from pH 1.4 in untreated ulcer patients to pH 2.5 to 3.5 for the bismuth agent CBS, see point 5.5 above]. For this reason the skilled practitioner seeking optimum pH conditions for bismuth precipitation would, in the appellants' opinion, not have chosen simultaneous administration to avoid precipitation taking place during the latency period of the H2-receptor blocker with the pH being below the optimum range but would have given preference to administration of the two active agents at different times.

This argument is not convincing. Firstly, bismuth preparations have for years successfully been administered as the sole active agent for the treatment of ulcer patients and were thus known to exhibit their beneficial therapeutic effect equally at a lower pH in the absence of an H2-receptor blocker (see in this respect Table VI at page 45 in (1/6); (2), especially page 697, line 5 from the bottom to page 698, line 9 from the bottom). Secondly, the results of the combined therapy provided in the Salmon paper (1/6) indicate a significantly increased early (4 weeks) healing of duodenal ulcers in spite of the fact that the bismuth agent was given prior to raising the intragastric pH by the administration of the H2- receptor blocker.

Accordingly, in contrast to the appellants' allegations, the skilled person would have reasonably concluded that any beneficial effect which could possibly be achieved by spacing apart the time of administration of the two drugs to allow raising the intragastric pH at the time of bismuth ingestion, would, if at all, only be marginal and would be outweighed by the simplified regimen afforded by simultaneous administration.

The appellants also relied on the argument that according to the prevailing expert's opinion at the priority date a significant rise in intragastric pH and, accordingly, the administration of an H2-receptor blocking anti-secretory agent, which would tend to raise the pH, should be avoided in connection with the administration of a bismuth agent, in order to favour tight adherence of the bismuth coating to the mucous layer of the ulcer or other lesion, because it was believed that at a higher pH the adherence was rapidly weakened and most of the coating would therefore be lost.

Apart from the fact that this argument, too, is unsubstantiated and entirely unsupported by any disclosure in the state of the art, it appears to be in contradiction with the appellants' assertion referred to in the foregoing two paragraphs that it would be beneficial to have raised the intragastric pH at the time of bismuth administration in order to achieve effective bismuth precipitation. Moreover, the appellants' view was at the priority date clearly obsolete in view of the fact that the beneficial results of the combined therapy reported in the Salmon paper (1/6) were achieved in spite of using a treatment regimen which involved ingestion of the H2-receptor blocker subsequent to bismuth administration.

5.7. All in all, having carefully studied the cited state of the art and the parties' submissions in the proceedings, the board cannot recognise a real prejudice or at least a good reason which would possibly have prevented the skilled person from the obvious solution of the problem defined above by combining a bismuth-containing agent and an H2-receptor blocking anti-secretory agent in a single pharmaceutical composition or by administration of said two agents simultaneously. Therefore, the board considers for the reasons given above that the main request and the second auxiliary request do not involve an inventive step.

5.8. In the claims of the first and third auxiliary requests the H2-receptor blocking anti-secretory agent was restricted to ranitidine which is likewise a well-known H2-receptor blocking anti-secretory agent, commercially available for years- see (3). Ranitidine is, for example, specifically referred to in citation (2) as an alternative to cimetidine and is said to have a greater ant-secretory effect than cimetidine (see page 699, lines 4 to 20). Ranitidine of course belongs to the class of H2-antagonists which are recommended at page 699 of (2) to be combined with tripotassium dicitrato bismuthate for simultaneous treatment of ulcer patients.

By reference to section 5.9 on page 225 of citation (3), the appellants themselves have admitted that cimetidine and ranitidine have remarkably similar absorption, distribution and elimination characteristics (see appellants' letter dated 26. January 1999, paragraph 4.20). It follows that on the basis of the disclosure of citations (2) and (3) the skilled person would consider ranitidine as an obvious alternative to cimetidine for the combined therapy of gastrointestinal disorders.

The appellants argued that, following the ingestion of ranitidine, the latency period required for raising the intragastric pH was longer than the corresponding period following administration of cimetidine and implied that this was a reason for a particular prejudice against simultaneous application of ranitidine and a bismuth agent. However, apart from the fact that this prejudice similarly finds no adequate support in the cited documents, it has already been noted in the foregoing point 5.6 that bismuth precipitation apparently takes place sufficiently and quickly at the untreated, normal intragastric pH of ulcer patients.

The further argument that, at the higher pH in the stomach resulting from the greater anti-secretory activity of ranitidine compared to cimetidine, the binding of the bismuth coating to the mucous layer was believed to be rapidly weakened with the consequence of detrimental effects in the treatment of gastrointestinal disorders is likewise entirely unsubstantiated. Moreover, with reference to what has been said in the last paragraph of point 5.6 above, this argument does not appear to be a good reason for the existence of a prejudice either.

5.9. In conclusion, the board cannot recognise a real prejudice or at least a good reason which would possibly have prevented the skilled person from the similar obvious solution of the problem defined above by combining a bismuth-containing agent and ranitidine in a single pharmaceutical composition or administration of said two agents simultaneously. Therefore, the board considers for the reasons given above that the first auxiliary request and the third auxiliary request do not involve an inventive step either.

5.10. Since for the reasons given in this decision it was, in the board's opinion, obvious for the skilled person to arrive at the proposed solution of the technical problem concerned, none of the requests could be considered to be acceptable under the terms of Article 52(1) in conjunction with Article 56 EPC, even if it were accepted that a more effective therapy for gastrointestinal disorders could possibly be achieved as an extra effect caused by the combined or simultaneous administration of the two active agents (see decision T 69/83, OJ EPO 1984, 357).